S
MLYS icon

SignatureFD’s Mineralys Therapeutics MLYS Stock Holding History

SignatureFD’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16K Buy
+117
New +$3.21K ﹤0.01% 3011
2025
Q2 		– Sell
-22
Closed -$349 – 3362
2025
Q1 		$349 Buy
+22
New +$253 ﹤0.01% 3207

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SignatureFD's MLYS Position: Q2 2026 in Review

SignatureFD opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 117 shares worth $3.16K. The stake represents ﹤0.01% of the portfolio and ranks #3011 among its holdings. This is a return to the name: SignatureFD previously reported a position in MLYS as recently as Q1 2025.

SignatureFD first reported a position in MLYS in Q1 2025 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • SignatureFD held 117 shares of Mineralys Therapeutics worth $3.16K as of Q2 2026.
  • Mineralys Therapeutics was a new SignatureFD position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3011 holding.
  • SignatureFD first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.